


Amendments to the Claims

Please amend the listing of claims as follows:

1. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms and a pharmaceutically acceptable excipient.
2. (Original) A pharmaceutical composition in accordance with claim 1, wherein said compound has a first gold(I) atom covalently bonded to a first carbon atom and a second gold(I) atom covalently bonded to a second carbon atom.
3. (Original) A pharmaceutical composition in accordance with claim 2, wherein said compound comprises a substituted or unsubstituted aromatic group as part of the covalent link.
4. (Currently Amended) A pharmaceutical composition in accordance with claim 2 ~~or 3~~, wherein the first carbon atom is part of a substituted or unsubstituted aromatic group.
5. (Original) A pharmaceutical composition in accordance with claim 4, wherein the substituted or unsubstituted aromatic group is a substituted or unsubstituted phenyl group.
6. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 2 ~~to 5~~, wherein the second carbon atom is part of a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group.
7. (Original) A pharmaceutical composition in accordance with claim 6, wherein the aromatic group of which the second carbon atom is a part is a substituted or unsubstituted phenyl group.
8. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 2 ~~to 7~~, wherein said compound incorporates a moiety having the formula:



where: Au¹ is said first gold (I) atom; Au² is said second gold (I) atom; C¹ is said first carbon atom; C² is said second carbon atom; Z is a linking group; and n is 0 or 1.


9. (Currently Amended) A pharmaceutical composition in accordance with ~~any preceding claim~~ claim 1, wherein said compound comprises a ligand bonded to each of said gold(I) atoms, each of said ligands being individually selected from the group consisting of PR₃, P(OR)₃, CNR, NCR, PR_n(CH₂OR[†])_{3-n}, N₄C₆H₁₂, [N₄C₆H₁₂-N-CH₃]⁺, PN₃C₆H₁₂, and P[N₃C₆H₁₂-N-CH₃]⁺, where R is a substituted or unsubstituted hydrocarbon moiety and R[†] is selected from the group consisting of H, Me, SO₂⁻, PO₃⁻, alkyl and aryl, and each R[†] in any one ligand is the same or different.

10. (Original) A pharmaceutical composition in accordance with claim 9, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

11. (Currently Amended) A pharmaceutical composition in accordance with claim 9-~~or 10~~, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.


12. (Currently Amended) A pharmaceutical composition in accordance with claim 9,~~10 or 11~~, wherein the ligand is PPh₃.

13. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of claims 1 to 7~~, wherein said compound has the formula:




where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO₃⁻, PO₄²⁻, CO₂H, OH, (CH₂)_nCH₃, O(CH₂)_nCH₃, S(CH₂)_nCH₃, or NR''''C(O)(R''''') where R'''' and R''''' are (CH₂)_nCH₃; and n is 0 to 6.

14. (Original) A pharmaceutical composition in accordance with claim 13, wherein said compound has a formula selected from the group consisting of:




15. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 ~~to~~ 7, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO₃⁻, PO₄²⁻, CO₂H, OH, (CH₂)_nCH₃, O(CH₂)_nCH₃, S(CH₂)_nCH₃, or NR''''C(O)(R''''') where R'''' and R''''' are (CH₂)_nCH₃; and n is 0 to 6.


16. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1-~~6~~-7, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO₃⁻, PO₄²⁻, CO₂H, OH, (CH₂)_nCH₃, O(CH₂)_nCH₃, S(CH₂)_nCH₃, or NR''''C(O)(R''''') where R'''' and R''''' are (CH₂)_nCH₃; and n is 0 to 6; and X is a linking group.


17. (Original) A pharmaceutical composition in accordance with claim 16, wherein X is selected from the group consisting of: O, S, PR or NR in which R is a substituted or unsubstituted hydrocarbon moiety.

18. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1-~~6~~-7, wherein said compound has the formula:




where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO₃⁻, PO₄²⁻, CO₂H, OH, (CH₂)_nCH₃, O(CH₂)_nCH₃, S(CH₂)_nCH₃, or NR''''C(O)(R''''') where R'''' and R''''' are (CH₂)_nCH₃; and n is 0 to 6.

19. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 1 ~~to~~ 7, wherein said compound has the formula:



Where Y is selected from the group consisting of $(R')_bAuL'$ and



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 or 3; b is 0 or 3; R''' is H, SO_3^- , PO_4^{2-} , CO_2H , OH, $(CH_2)_nCH_3$, $O(CH_2)_nCH_3$, $S(CH_2)_nCH_3$, or $NR''''C(O)(R''''')$ where R'''' and R''''' are $(CH_2)_nCH_3$; and n is 0 to 6.

20. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 13 ~~to~~ 19, wherein L and L' are independently selected from the group consisting of PR_3 , $P(OR)_3$, CNR, NCR, $PR_n(CH_2OR^\dagger)_{3-n}$, $N_4C_6H_{12}$, $[N_4C_6H_{12}-N-CH_3]^+$, $PN_3C_6H_{12}$, and $P[N_3C_6H_{12}-N-CH_3]^+$, where R is a substituted or unsubstituted hydrocarbon moiety and R^\dagger is selected from the group consisting of H, Me, SO_2^- , PO_3^- , alkyl and aryl, and each R^\dagger in any one ligand is the same or different.

21. (Original) A pharmaceutical composition in accordance with claim 20, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.

22. (Currently Amended) A pharmaceutical composition in accordance with claim 20 ~~or~~ 21, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.

23. (Currently Amended) A pharmaceutical composition in accordance with claim 20, ~~21 or 22~~, wherein the ligand is PPh₃.

24. (Currently Amended) A pharmaceutical composition in accordance with ~~any one of~~ claims 13 ~~to 23~~, wherein R' and R'' are each independently selected from the group consisting of methylene, ethylene, propylene, butylene and phenylene groups.

25. (Original) A compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms for use as a chemotherapeutic agent.

26.-30. (Canceled)

31. (Original) A method of treating a cancer in a human or animal patient comprising administering to said patient a therapeutically effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms.

32. (Original) A method in accordance with claim 31, wherein the cancer is resistant to a platinum drug.

33. (Original) A method in accordance with claim 32, wherein the cancer is resistant to cisplatinum and/or carboplatinum.

34. (Currently Amended) A method in accordance with claim 31, ~~32 or 33~~, wherein the cancer is ovarian or lung cancer.

35. (Canceled)

36. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom, and a pharmaceutically acceptable excipient.

37. (Original) A pharmaceutical composition in accordance with claim 36, wherein said second gold atom is a gold(III) atom.

38. (Original) A compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom for use as a chemotherapeutic agent.

39. (Canceled)

40. (Original) A method of treating a cancer in a human or animal patient comprising administering to said patient a therapeutically effective amount of a compound having a first gold atom which is a gold(III) atom and a second gold atom which is either a gold(I) atom or a gold(III) atom, each of said first and second gold atoms being covalently bonded to a carbon atom in a covalent link connecting the first and second gold atoms, and the or each gold(III) atom being reducible, *in vivo*, to a gold(I) atom.